Sprycel

In the US, Sprycel (dasatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Leukemia.

US matches:

• Sprycel

UK matches:

• Sprycel 20mg, 50mg, 70mg and 100mg Film-Coated Tablets (SPC)

Ingredient matches for Sprycel

Dasatinib

Dasatinib is reported as an ingredient of Sprycel in the following countries:

• Australia


• Canada


• Denmark


• Indonesia


• New Zealand


• Poland


• Slovenia


• Switzerland

Dasatinib monohydrate (a derivative of Dasatinib) is reported as an ingredient of Sprycel in the following countries:

• Argentina


• Austria


• Belgium


• Czech Republic


• France


• Germany


• Hungary


• Ireland


• Italy


• Japan


• Luxembourg


• Netherlands


• Norway


• Oman


• Spain


• Sweden


• Switzerland


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.